Department of Health and Human Services, National Institutes of Health

Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)

Who can apply

  • Public and tribal housing authorities
  • Special district governments
  • Private colleges and universities
  • County governments
  • Tribal organizations
  • Nonprofits with 501(c)(3) status
  • City or township governments
  • Federally recognized tribal governments
  • State governments
  • Small businesses
  • Public and state-controlled colleges
  • Independent school districts
  • Others (see eligibility details)
  • For-profit organizations (not small businesses)
  • Nonprofits without 501(c)(3) status

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

About this grant

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms. To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through investigational new drugs (IND) studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.

Topics

GrantCalendar is not affiliated with Department of Health and Human Services. Details can change, so confirm everything on the official listing before you apply. Spotted a mistake? Tell us.

Similar open grants

Get new grants every Monday

One short email with new grants and deadlines coming up in the next two weeks. Unsubscribe in one click.